Principles and Practice of Psychopharmacotherapy (PRINCIPLES & PRAC PSYCHOPHARMACOTHERAPY (JANICAK))
Format: PDF / Kindle (mobi) / ePub
The fully updated Fourth Edition of this comprehensive clinical reference summarizes the latest data on hundreds of drug and device-based therapies and offers practical, evidence-based guidelines and treatment strategies for virtually every psychiatric disorder. Coverage includes the recently FDA-approved use of vagus nerve stimulation for treatment-resistant depression and current clinical guidelines on electroconvulsive therapy and transcranial magnetic stimulation, including indications, dosage, variations in treatment, and administration. Other topics addressed include the risks and benefits of psychopharmacotherapy for the pregnant, child, adolescent, geriatric, and dementia patient, and up-to-the-minute strategies for treating schizophrenia, bipolar disorder, anxiety, sleep disorders, obsessive-compulsive and panic disorders, dementia, and more.
There are side effects associated with these medications, such as dry mouth, blurred vision, confusion, urinary retention, and, very rarely, paralytic ileus. Dental caries and diverticula may occur with chronic use. Patients can develop behavioral toxicity, which in its severe form may be characterized by disorientation, loss of immediate memory, and florid hallucinations. The expense of treatment is increased. Anticholinergics can produce a feeling of euphoria and can be abused. Arguments in
Olanzapine in the treatment of schizoaffective disorder. Presented at the 36th Annual NCDEU Meeting. Boca Raton, FL, May 1996. 119. Beasley CM Jr, Beuzen JN, Birkett MA, et al. Olanzapine versus clozapine: an international double-blind study of the treatment of resistant schizophrenia. New Research, Annual Meeting of the American Psychiatric Association, Washington, DC, May 15–20, 1999;NR260:136. 120. Procyshyn RM, Zerjav S. Drug utilization pattern and outcomes associated with in-hospital
256). This drug has perhaps the most complicated dosing schedule of any antidepressant. The current dosing guidelines for the immediate release formulation is for twice daily dosing. For that reason, an extended release version is in development. The hope is that it will simplify dosing guidelines. Of note, one of the authors (SHP) conducted a study showing that 85% of patients who responded to acute treatment with the immediate release formulation of nefazodone using a twice daily dosing
Psychiatry 1974;131:191–198. 405. Frank E, Kupfer D, Perel J, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093–1099. 406. Fava GA, Rafanelli C, Grandi S, et al. Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry 1998;55:816–820. 407. Baldessarini R. Current status of antidepressants: clinical pharmacology and therapy. J Clin Psychiatry 1989;50:117–126. 408. Richelson E.
switch in comparison with standard heterocyclic antidepressants. Another example is the avoidance of benzodiazepines for the treatment of panic disorder in a patient with a history of alcohol or sedative-hypnotic abuse due to the increased risk of misuse or dependency. In this situation, a selective serotonin reuptake inhibitor (SSRI) may be more appropriate. Assessment of physical, as well as psychiatric status, is also critically important. The presence of intercurrent medical disorders, as